Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX)

Schonfeld Strategic Advisors LLC lessened its stake in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 92.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 47,300 shares of the company's stock after selling 589,091 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Annexon were worth $243,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Annexon by 11.6% during the 4th quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company's stock valued at $28,456,000 after acquiring an additional 576,625 shares during the period. Candriam S.C.A. lifted its position in shares of Annexon by 15.6% during the 4th quarter. Candriam S.C.A. now owns 2,534,230 shares of the company's stock valued at $13,001,000 after acquiring an additional 341,431 shares during the period. Geode Capital Management LLC lifted its position in shares of Annexon by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company's stock valued at $11,142,000 after acquiring an additional 27,843 shares during the period. Dimensional Fund Advisors LP raised its holdings in Annexon by 20.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,360,076 shares of the company's stock worth $6,977,000 after buying an additional 231,034 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Annexon by 6.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,104,385 shares of the company's stock worth $5,667,000 after buying an additional 69,733 shares during the last quarter.

Annexon Stock Up 4.0%

ANNX traded up $0.08 during trading on Monday, hitting $2.09. 1,655,590 shares of the company's stock were exchanged, compared to its average volume of 1,782,885. The business's 50 day moving average is $1.90 and its two-hundred day moving average is $3.59. Annexon, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $7.85. The stock has a market cap of $229.30 million, a P/E ratio of -1.99 and a beta of 1.24.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, sell-side analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on ANNX shares. HC Wainwright lowered their price objective on shares of Annexon from $20.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Needham & Company LLC lowered their price objective on shares of Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.